CAMBRIDGE, Mass. – November 30, 2010 – Selventa™, which evolved from Genstruct®, Inc. today announced that it has changed its name and launched a re-branded website as part of an initiative to provide innovative solutions for its client partners. The company’s core strengths embrace a customer-focused approach that leverages existing patient data and innovative analytics to help pharmaceutical and biotechnology partners accelerate development and clarify decisions on therapeutics and diagnostics.
“Selventa‘s new business strategy enables us to partner with clients at a deeper level to help them solve project portfolio development challenges and make a bigger impact on drug discovery,” said David de Graaf, Ph.D., Chief Scientific Officer of Selventa. “The new company name, which is derived from a word meaning clarity, reflects our new focused approach.”
In addition to the company’s name change, Selventa has embarked upon an entire corporate re-branding effort as demonstrated by its new corporate website (www.selventa.com). The updated content is more emblematic of the company’s commitment to consulting services, licensed software products and strategic partnerships that help clients find optimal treatments for the right patients. Selventa works with a variety of clients in the pharmaceutical, biotechnology and life science industries as well as academic institutions.
“As a personalized healthcare organization, we are addressing global industry challenges and critical needs in the research and development continuum,” said Louis Latino, Selventa’s Executive Vice President of Sales and Marketing. “The company based these changes on client input and will continue to integrate new ideas with existing programs for future initiatives.”
About Selventa
Founded in 2002 and privately-held, Selventa helps clients find optimal treatments for the right patients by offering scientific consulting services, licensed software products and strategic partnerships. The company analyzes rich patient data, accelerates the development process and clarifies decisions on therapeutics and diagnostics. Selventa engages in short-, mid- and long-term relationships with top-tier pharmaceutical and life science companies to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases, inflammation and drug safety. For more information, visit www.selventa.com.
For more information, please contact: Diane H. Song, Ph.D., 617-547-5421 x235 dsong@selventa.com
Paul Kidwell, 617-296-3854 paulkidwell@comcast.net
